www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2120

Title: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids
Authors: van Staa, TP
GEUSENS, Piet
Pols, HAP
de Laet, C
Leufkens, HGM
Cooper, C
Issue Date: 2005
Publisher: OXFORD UNIV PRESS
Citation: QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 98(3). p. 191-198
Abstract: Background: Previous analyses of risk factors for glucocorticoid (GC)-induced osteoporosis have focused on the estimation of relative rather than absolute fracture probability. Aim: To estimate risk scores for the individual probability of fracture in GC users. Design: Retrospective data analysis. Methods: We evaluated all patients aged 40 years or older with a prescription for oral GCs in the General Practice Research Database (GPRD), which comprises the computerized medical records of around 7 million UK subjects. Individual risk factors for osteoporotic fractures were identified, and combined in a predictive model for 10-year absolute fracture risk. Results: Of 191 752 oral GC users aged greater than or equal to40 years, 7412 experienced an osteoporotic fracture. Several characteristics independently contributed to the fracture risk score (GC therapy, age, gender, fall history, fracture history, body mass index, smoking, previous diagnoses, use of medication, recent hospitalization and indication for GC treatment). Scores of 30, 40 and 50 corresponded to absolute 5-year fracture risks of 6.2%, 15.3% and 35.2%, respectively. A woman aged 65 years with RA, low BMI, and a previous history of fracture and falls, who used 15 mg GC daily (total risk score 54) would have a 5-year fracture risk of 47% (a man with similar history, 30.1%). Short-term use of high-dose GC therapy (greater than or equal to30 mg) was associated with only a small increased risk of osteoporotic fracture (RR 1.21, 95%CI 1.04-1.42) in patients with a history of GC use. Discussion: This risk score helps to predict an individual's risk of fracture during GC use. Decisions about bone protection treatment could be based on long-term risks of fracture.
Notes: Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands. Univ Southampton, MRC Epidemiol Resource Ctr, Southampton, Hants, England. Procter & Gamble Pharmaceut, Egham, Surrey, England. Univ Hosp, Dept Rheumatol, Maastricht, Netherlands. Limburgs Univ Ctr, Diepenbeek, Belgium. Erasmus Univ, Med Ctr, Rotterdam, Netherlands.Cooper, C, Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England.cc@mrc.soton.ac.uk
URI: http://hdl.handle.net/1942/2120
DOI: 10.1093/qjmed/hci029
ISI #: 000227244800004
ISSN: 1460-2725
Category: A1
Type: Journal Contribution
Validation: ecoom, 2006
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.